WATCH THE WEBINAR RECORDING
Abstract:
This webinar explores how incorporating multiple clinically relevant outcomes into a single Net Treatment Benefit (NTB) assessment can transform rare disease clinical trials. By engaging patient advocates and clinicians early in trial design, this approach enhances patient-centricity and clinical relevance while also reducing sample size, shortening development timelines and trial budgets, and increasing the quality of clinical insights.
Key Takeaways:
- Elevate the discussion around clinical trial endpoints by exploring how more patient-focused and holistic approach can enhance the way rare disease clinical trials are run.
- Two main benefits from this innovative approach.
Speakers:
- Dr. Sébastien Coppe – Chief Executive Officer, One2Treat
- Dr. Pascal Piedbois – Chief Medical Officer, One2Treat
One2Treat is a forward-thinking partner for biopharmaceuticals companies dedicated to delivering transformative insights in clinical trial design analysis and market access evaluations to support holistic treatment decisions. One2Treat was founded in July 2023 after 4 years of advanced research and software development incubation within Bright Roads. Driven by a commitment to patient-centricity, One2Treat leverages modern statistical methodologies and advanced software solutions ushering in a new era of personalized healthcare.
Get The Presentation Now
Fields marked with an * are required.
